Mar 7, 2024 MM120 for Generalized Anxiety Disorder (GAD): Phase 2b Full Topline Data, ODT PK Bridging Study, Breakthrough Therapy Designation
Jun 6, 2024 MindMed ICPR 2024: Rapid and Durable Response to a Single Dose of MM120 (Lysergide) in Generalized Anxiety Disorder: A Dose-Optimization Study
May 29, 2024 MindMed ASCP 2024: Improvement in Functional and Sexual Disability and Quality of Life After One Dose of MM120 (Lysergide) in Generalized Anxiety Disorder
May 29, 2024 MindMed ASCP 2024: Rapid and Durable Response to a Single Dose of MM120 (Lysergide) in Generalized Anxiety Disorder: A Dose-Optimization Study
May 6, 2024 MindMed ISPOR 2024: Work Productivity and Activity Impairment Associated with Generalized Anxiety Disorder among Adults in the United States
May 6, 2024 MindMed ISPOR 2024: Health-related Quality of Life Associated with Generalized Anxiety Disorder among Adults in the United States
May 6, 2024 MindMed ISPOR 2024: Health Care Resource Use Associated with Generalized Anxiety Disorder among Adults in the United States
May 4, 2024 MindMed APA 2024: Rapid and Durable Response to a Single Dose of MM120 (Lysergide) in Generalized Anxiety Disorder: A Dose-Optimization Study
May 4, 2024 MindMed APA 2024: Screening Adults in the US General Population to Detect Cases of Undiagnosed Generalized Anxiety Disorder
May 4, 2024 MindMed APA 2024: Quantifying the Burden of Undiagnosed Generalized Anxiety Disorder in the US
Apr 24, 2024 MindMed ADAA 2024: U.S. Generalized Anxiety Disorder Related to COVID-19 Pandemic by Age and Gender
Apr 24, 2024 MindMed EPA 2024: Prevalence of Generalized Anxiety Disorder Among Five European Countries Before and During COVID
